The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 21, 2021

Filed:

Nov. 04, 2016
Applicant:

Genuone Sciences Inc., Seoul, KR;

Inventors:

Yong-baik Cho, Gyeonggi-do, KR;

Seul-ki Kim, Sejong, KR;

Sang-Back Kim, Seoul, KR;

Jae-hyuck Shin, Seoul, KR;

Young-ran Um, Sejong, KR;

So-youn Mok, Chungcheongnam-do, KR;

Ju-ri Jung, Seoul, KR;

Soon-min Lim, Sejong, KR;

Chae Shin Seo, Daegu, KR;

Hong Koo Cho, Seoul, KR;

Bon Am Koo, Seoul, KR;

Hyo Jin Jeon, Gyeonggi-do, KR;

Han-Seok Choi, Gyeonggi-do, KR;

Ye Jin Kim, Incheon, KR;

Assignee:
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 36/285 (2006.01); A61K 36/9068 (2006.01); A61K 36/185 (2006.01); A23L 33/105 (2016.01); A61K 36/28 (2006.01); A61P 1/00 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 36/285 (2013.01); A23L 33/105 (2016.08); A61K 9/0053 (2013.01); A61K 9/0056 (2013.01); A61K 36/185 (2013.01); A61K 36/28 (2013.01); A61K 36/9068 (2013.01); A61P 1/00 (2018.01); A23V 2002/00 (2013.01); A61K 2236/331 (2013.01); A61K 2236/333 (2013.01);
Abstract

Provided is a pharmaceutical composition for preventing or treating inflammatory bowel disease (IBD) comprising a mixed extract of at least two ofDecne,Retzius, andRosc. as an active ingredient and a method thereof, and more specifically, to a pharmaceutical composition having an inhibitory effect on monocyte adhesion in intestinal epithelial cells, an effect of inhibiting the production of inflammatory cytokines, an effect of ameliorating colitis in an animal model of dextran sodium sulfate (DSS)-induced colitis, and an effect of ameliorating Crohn's disease in an animal model of 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced Crohn's disease.


Find Patent Forward Citations

Loading…